Linifanib (ABT-869), enhances cytotoxicity with poly (ADP-ribose) polymerase inhibitor, veliparib (ABT-888), in head and neck carcinoma cells.
Identifieur interne : 002433 ( Main/Exploration ); précédent : 002432; suivant : 002434Linifanib (ABT-869), enhances cytotoxicity with poly (ADP-ribose) polymerase inhibitor, veliparib (ABT-888), in head and neck carcinoma cells.
Auteurs : Heng-Wei Hsu [États-Unis] ; Rosalia De Necochea-Campion [États-Unis] ; Vonetta Williams [États-Unis] ; Penelope J. Duerksen-Hughes [États-Unis] ; Alfred A. Simental [États-Unis] ; Robert L. Ferris [États-Unis] ; Chien-Shing Chen [États-Unis] ; Saied Mirshahidi [États-Unis]Source :
- Oral oncology [ 1879-0593 ] ; 2014.
Descripteurs français
- KwdFr :
- Apoptose (), Benzimidazoles (pharmacologie), Carcinome épidermoïde (traitement médicamenteux), Cassures de l'ADN (), Histone (métabolisme), Humains, Indazoles (pharmacologie), Inhibiteurs de poly(ADP-ribose) polymérases, Lignée cellulaire tumorale, Phénylurées (pharmacologie), Poly(ADP-ribose) polymerases (métabolisme), Rad51 Recombinase (métabolisme), Survie cellulaire (), Tumeurs de la tête et du cou (traitement médicamenteux).
- MESH :
- métabolisme : Histone, Poly(ADP-ribose) polymerases, Rad51 Recombinase.
- pharmacologie : Benzimidazoles, Indazoles, Phénylurées.
- traitement médicamenteux : Carcinome épidermoïde, Tumeurs de la tête et du cou.
- Apoptose, Cassures de l'ADN, Humains, Inhibiteurs de poly(ADP-ribose) polymérases, Lignée cellulaire tumorale, Survie cellulaire.
English descriptors
- KwdEn :
- Apoptosis (drug effects), Benzimidazoles (pharmacology), Carcinoma, Squamous Cell (drug therapy), Cell Line, Tumor, Cell Survival (drug effects), DNA Breaks (drug effects), Head and Neck Neoplasms (drug therapy), Histones (metabolism), Humans, Indazoles (pharmacology), Phenylurea Compounds (pharmacology), Poly(ADP-ribose) Polymerase Inhibitors, Poly(ADP-ribose) Polymerases (metabolism), Rad51 Recombinase (metabolism).
- MESH :
- chemical , metabolism : Histones, Poly(ADP-ribose) Polymerases, Rad51 Recombinase.
- chemical , pharmacology : Benzimidazoles, Indazoles, Phenylurea Compounds.
- drug effects : Apoptosis, Cell Survival, DNA Breaks.
- drug therapy : Carcinoma, Squamous Cell, Head and Neck Neoplasms.
- Cell Line, Tumor, Humans, Poly(ADP-ribose) Polymerase Inhibitors.
Abstract
PARP inhibitors (PARPi) may provide an opportunity to gain selective killing of tumor cells which have deficiencies in cellular DNA repair systems. We previously demonstrated linifanib (ABT-869), a multi-receptor tyrosine kinase inhibitor of VEGF and PDGF receptor families, radiosensitized Head and Neck Squamous Cell Carcinoma cells (HNSCC) via inhibiting STAT3 activation. Given that STAT3 can modulate DNA damage response (DDR) pathway, in this study, we evaluate the effects of linifanib to enhance cytotoxicity with the PARPi, veliparib (ABT-888), in HNSCC.
DOI: 10.1016/j.oraloncology.2014.03.006
PubMed: 24735547
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002533
- to stream PubMed, to step Curation: 002523
- to stream PubMed, to step Checkpoint: 002523
- to stream Ncbi, to step Merge: 001B29
- to stream Ncbi, to step Curation: 001B29
- to stream Ncbi, to step Checkpoint: 001B29
- to stream Main, to step Merge: 002533
- to stream Main, to step Curation: 002433
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Linifanib (ABT-869), enhances cytotoxicity with poly (ADP-ribose) polymerase inhibitor, veliparib (ABT-888), in head and neck carcinoma cells.</title><author><name sortKey="Hsu, Heng Wei" sort="Hsu, Heng Wei" uniqKey="Hsu H" first="Heng-Wei" last="Hsu">Heng-Wei Hsu</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pharmacology, Loma Linda University, Loma Linda, CA, USA; Department of Basic Sciences, Loma Linda University, Loma Linda, CA, USA; LLU Cancer Center Biospecimen Laboratory, Loma Linda University, Loma Linda, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pharmacology, Loma Linda University, Loma Linda, CA, USA; Department of Basic Sciences, Loma Linda University, Loma Linda, CA, USA; LLU Cancer Center Biospecimen Laboratory, Loma Linda University, Loma Linda, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="De Necochea Campion, Rosalia" sort="De Necochea Campion, Rosalia" uniqKey="De Necochea Campion R" first="Rosalia" last="De Necochea-Campion">Rosalia De Necochea-Campion</name><affiliation wicri:level="2"><nlm:affiliation>LLU Cancer Center Biospecimen Laboratory, Loma Linda University, Loma Linda, CA, USA; Division of Oncology & Hematology, Loma Linda University, Loma Linda, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>LLU Cancer Center Biospecimen Laboratory, Loma Linda University, Loma Linda, CA, USA; Division of Oncology & Hematology, Loma Linda University, Loma Linda, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Williams, Vonetta" sort="Williams, Vonetta" uniqKey="Williams V" first="Vonetta" last="Williams">Vonetta Williams</name><affiliation wicri:level="2"><nlm:affiliation>Department of Basic Sciences, Loma Linda University, Loma Linda, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Basic Sciences, Loma Linda University, Loma Linda, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Duerksen Hughes, Penelope J" sort="Duerksen Hughes, Penelope J" uniqKey="Duerksen Hughes P" first="Penelope J" last="Duerksen-Hughes">Penelope J. Duerksen-Hughes</name><affiliation wicri:level="2"><nlm:affiliation>Department of Basic Sciences, Loma Linda University, Loma Linda, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Basic Sciences, Loma Linda University, Loma Linda, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Simental, Alfred A" sort="Simental, Alfred A" uniqKey="Simental A" first="Alfred A" last="Simental">Alfred A. Simental</name><affiliation wicri:level="2"><nlm:affiliation>Department of Otolaryngology and Head/Neck Surgery, Loma Linda University, Loma Linda, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Otolaryngology and Head/Neck Surgery, Loma Linda University, Loma Linda, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Ferris, Robert L" sort="Ferris, Robert L" uniqKey="Ferris R" first="Robert L" last="Ferris">Robert L. Ferris</name><affiliation wicri:level="4"><nlm:affiliation>Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region><settlement type="city">Pittsburgh</settlement></placeName><orgName type="university">Université de Pittsburgh</orgName></affiliation></author><author><name sortKey="Chen, Chien Shing" sort="Chen, Chien Shing" uniqKey="Chen C" first="Chien-Shing" last="Chen">Chien-Shing Chen</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Loma Linda University, Loma Linda, CA, USA; LLU Cancer Center Biospecimen Laboratory, Loma Linda University, Loma Linda, CA, USA; Division of Oncology & Hematology, Loma Linda University, Loma Linda, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Loma Linda University, Loma Linda, CA, USA; LLU Cancer Center Biospecimen Laboratory, Loma Linda University, Loma Linda, CA, USA; Division of Oncology & Hematology, Loma Linda University, Loma Linda, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Mirshahidi, Saied" sort="Mirshahidi, Saied" uniqKey="Mirshahidi S" first="Saied" last="Mirshahidi">Saied Mirshahidi</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Loma Linda University, Loma Linda, CA, USA; Department of Basic Sciences, Loma Linda University, Loma Linda, CA, USA; LLU Cancer Center Biospecimen Laboratory, Loma Linda University, Loma Linda, CA, USA. Electronic address: smirshahidi@llu.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Loma Linda University, Loma Linda, CA, USA; Department of Basic Sciences, Loma Linda University, Loma Linda, CA, USA; LLU Cancer Center Biospecimen Laboratory, Loma Linda University, Loma Linda, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24735547</idno><idno type="pmid">24735547</idno><idno type="doi">10.1016/j.oraloncology.2014.03.006</idno><idno type="wicri:Area/PubMed/Corpus">002533</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002533</idno><idno type="wicri:Area/PubMed/Curation">002523</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002523</idno><idno type="wicri:Area/PubMed/Checkpoint">002523</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002523</idno><idno type="wicri:Area/Ncbi/Merge">001B29</idno><idno type="wicri:Area/Ncbi/Curation">001B29</idno><idno type="wicri:Area/Ncbi/Checkpoint">001B29</idno><idno type="wicri:Area/Main/Merge">002533</idno><idno type="wicri:Area/Main/Curation">002433</idno><idno type="wicri:Area/Main/Exploration">002433</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Linifanib (ABT-869), enhances cytotoxicity with poly (ADP-ribose) polymerase inhibitor, veliparib (ABT-888), in head and neck carcinoma cells.</title><author><name sortKey="Hsu, Heng Wei" sort="Hsu, Heng Wei" uniqKey="Hsu H" first="Heng-Wei" last="Hsu">Heng-Wei Hsu</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pharmacology, Loma Linda University, Loma Linda, CA, USA; Department of Basic Sciences, Loma Linda University, Loma Linda, CA, USA; LLU Cancer Center Biospecimen Laboratory, Loma Linda University, Loma Linda, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pharmacology, Loma Linda University, Loma Linda, CA, USA; Department of Basic Sciences, Loma Linda University, Loma Linda, CA, USA; LLU Cancer Center Biospecimen Laboratory, Loma Linda University, Loma Linda, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="De Necochea Campion, Rosalia" sort="De Necochea Campion, Rosalia" uniqKey="De Necochea Campion R" first="Rosalia" last="De Necochea-Campion">Rosalia De Necochea-Campion</name><affiliation wicri:level="2"><nlm:affiliation>LLU Cancer Center Biospecimen Laboratory, Loma Linda University, Loma Linda, CA, USA; Division of Oncology & Hematology, Loma Linda University, Loma Linda, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>LLU Cancer Center Biospecimen Laboratory, Loma Linda University, Loma Linda, CA, USA; Division of Oncology & Hematology, Loma Linda University, Loma Linda, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Williams, Vonetta" sort="Williams, Vonetta" uniqKey="Williams V" first="Vonetta" last="Williams">Vonetta Williams</name><affiliation wicri:level="2"><nlm:affiliation>Department of Basic Sciences, Loma Linda University, Loma Linda, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Basic Sciences, Loma Linda University, Loma Linda, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Duerksen Hughes, Penelope J" sort="Duerksen Hughes, Penelope J" uniqKey="Duerksen Hughes P" first="Penelope J" last="Duerksen-Hughes">Penelope J. Duerksen-Hughes</name><affiliation wicri:level="2"><nlm:affiliation>Department of Basic Sciences, Loma Linda University, Loma Linda, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Basic Sciences, Loma Linda University, Loma Linda, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Simental, Alfred A" sort="Simental, Alfred A" uniqKey="Simental A" first="Alfred A" last="Simental">Alfred A. Simental</name><affiliation wicri:level="2"><nlm:affiliation>Department of Otolaryngology and Head/Neck Surgery, Loma Linda University, Loma Linda, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Otolaryngology and Head/Neck Surgery, Loma Linda University, Loma Linda, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Ferris, Robert L" sort="Ferris, Robert L" uniqKey="Ferris R" first="Robert L" last="Ferris">Robert L. Ferris</name><affiliation wicri:level="4"><nlm:affiliation>Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region><settlement type="city">Pittsburgh</settlement></placeName><orgName type="university">Université de Pittsburgh</orgName></affiliation></author><author><name sortKey="Chen, Chien Shing" sort="Chen, Chien Shing" uniqKey="Chen C" first="Chien-Shing" last="Chen">Chien-Shing Chen</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Loma Linda University, Loma Linda, CA, USA; LLU Cancer Center Biospecimen Laboratory, Loma Linda University, Loma Linda, CA, USA; Division of Oncology & Hematology, Loma Linda University, Loma Linda, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Loma Linda University, Loma Linda, CA, USA; LLU Cancer Center Biospecimen Laboratory, Loma Linda University, Loma Linda, CA, USA; Division of Oncology & Hematology, Loma Linda University, Loma Linda, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Mirshahidi, Saied" sort="Mirshahidi, Saied" uniqKey="Mirshahidi S" first="Saied" last="Mirshahidi">Saied Mirshahidi</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Loma Linda University, Loma Linda, CA, USA; Department of Basic Sciences, Loma Linda University, Loma Linda, CA, USA; LLU Cancer Center Biospecimen Laboratory, Loma Linda University, Loma Linda, CA, USA. Electronic address: smirshahidi@llu.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Loma Linda University, Loma Linda, CA, USA; Department of Basic Sciences, Loma Linda University, Loma Linda, CA, USA; LLU Cancer Center Biospecimen Laboratory, Loma Linda University, Loma Linda, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author></analytic><series><title level="j">Oral oncology</title><idno type="eISSN">1879-0593</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Apoptosis (drug effects)</term><term>Benzimidazoles (pharmacology)</term><term>Carcinoma, Squamous Cell (drug therapy)</term><term>Cell Line, Tumor</term><term>Cell Survival (drug effects)</term><term>DNA Breaks (drug effects)</term><term>Head and Neck Neoplasms (drug therapy)</term><term>Histones (metabolism)</term><term>Humans</term><term>Indazoles (pharmacology)</term><term>Phenylurea Compounds (pharmacology)</term><term>Poly(ADP-ribose) Polymerase Inhibitors</term><term>Poly(ADP-ribose) Polymerases (metabolism)</term><term>Rad51 Recombinase (metabolism)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Apoptose ()</term><term>Benzimidazoles (pharmacologie)</term><term>Carcinome épidermoïde (traitement médicamenteux)</term><term>Cassures de l'ADN ()</term><term>Histone (métabolisme)</term><term>Humains</term><term>Indazoles (pharmacologie)</term><term>Inhibiteurs de poly(ADP-ribose) polymérases</term><term>Lignée cellulaire tumorale</term><term>Phénylurées (pharmacologie)</term><term>Poly(ADP-ribose) polymerases (métabolisme)</term><term>Rad51 Recombinase (métabolisme)</term><term>Survie cellulaire ()</term><term>Tumeurs de la tête et du cou (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Histones</term><term>Poly(ADP-ribose) Polymerases</term><term>Rad51 Recombinase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Benzimidazoles</term><term>Indazoles</term><term>Phenylurea Compounds</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Apoptosis</term><term>Cell Survival</term><term>DNA Breaks</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Carcinoma, Squamous Cell</term><term>Head and Neck Neoplasms</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Histone</term><term>Poly(ADP-ribose) polymerases</term><term>Rad51 Recombinase</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Benzimidazoles</term><term>Indazoles</term><term>Phénylurées</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Carcinome épidermoïde</term><term>Tumeurs de la tête et du cou</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Cell Line, Tumor</term><term>Humans</term><term>Poly(ADP-ribose) Polymerase Inhibitors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Apoptose</term><term>Cassures de l'ADN</term><term>Humains</term><term>Inhibiteurs de poly(ADP-ribose) polymérases</term><term>Lignée cellulaire tumorale</term><term>Survie cellulaire</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">PARP inhibitors (PARPi) may provide an opportunity to gain selective killing of tumor cells which have deficiencies in cellular DNA repair systems. We previously demonstrated linifanib (ABT-869), a multi-receptor tyrosine kinase inhibitor of VEGF and PDGF receptor families, radiosensitized Head and Neck Squamous Cell Carcinoma cells (HNSCC) via inhibiting STAT3 activation. Given that STAT3 can modulate DNA damage response (DDR) pathway, in this study, we evaluate the effects of linifanib to enhance cytotoxicity with the PARPi, veliparib (ABT-888), in HNSCC.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Californie</li><li>Pennsylvanie</li></region><settlement><li>Pittsburgh</li></settlement><orgName><li>Université de Pittsburgh</li></orgName></list><tree><country name="États-Unis"><region name="Californie"><name sortKey="Hsu, Heng Wei" sort="Hsu, Heng Wei" uniqKey="Hsu H" first="Heng-Wei" last="Hsu">Heng-Wei Hsu</name></region><name sortKey="Chen, Chien Shing" sort="Chen, Chien Shing" uniqKey="Chen C" first="Chien-Shing" last="Chen">Chien-Shing Chen</name><name sortKey="De Necochea Campion, Rosalia" sort="De Necochea Campion, Rosalia" uniqKey="De Necochea Campion R" first="Rosalia" last="De Necochea-Campion">Rosalia De Necochea-Campion</name><name sortKey="Duerksen Hughes, Penelope J" sort="Duerksen Hughes, Penelope J" uniqKey="Duerksen Hughes P" first="Penelope J" last="Duerksen-Hughes">Penelope J. Duerksen-Hughes</name><name sortKey="Ferris, Robert L" sort="Ferris, Robert L" uniqKey="Ferris R" first="Robert L" last="Ferris">Robert L. Ferris</name><name sortKey="Mirshahidi, Saied" sort="Mirshahidi, Saied" uniqKey="Mirshahidi S" first="Saied" last="Mirshahidi">Saied Mirshahidi</name><name sortKey="Simental, Alfred A" sort="Simental, Alfred A" uniqKey="Simental A" first="Alfred A" last="Simental">Alfred A. Simental</name><name sortKey="Williams, Vonetta" sort="Williams, Vonetta" uniqKey="Williams V" first="Vonetta" last="Williams">Vonetta Williams</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002433 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002433 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Amérique
|area= PittsburghV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:24735547
|texte= Linifanib (ABT-869), enhances cytotoxicity with poly (ADP-ribose) polymerase inhibitor, veliparib (ABT-888), in head and neck carcinoma cells.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24735547" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PittsburghV1
| This area was generated with Dilib version V0.6.38. |  |